- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is testing a new inhaled medicine, saralutinib, for people with pulmonary arterial hypertension (PAH). Researchers want to see if it helps patients walk further in six minutes and improves their health compared to a dummy inhaler.
For: Pulmonary Arterial HypertensionSpain · Lithuania · Greece - AuthorisedTherapeutic exploratory (Phase II)
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, Usnoflast, for adults with Amyotrophic Lateral Sclerosis (ALS). It aims to see if the medicine can slow down the disease and if it's safe. Participants will receive either Usnoflast or a placebo (dummy medicine) for 36 weeks.
For: Amyotrophic Lateral Sclerosis (ALS)Spain · Germany · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants with Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, LY4100511, for adults with moderate to severe plaque psoriasis. It's a Phase 2 trial, meaning it's an early stage to see how well the medicine works and if it's safe, compared to a dummy pill.
For: Plaque PsoriasisHungary · Poland · Czechia